Short answer
ARDELYX, INC. (ARDX) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $110M (up 12.3% year over year) with net income of −$969,000.
Q3 2025 key financials · XBRL
- Revenue
- $110M
- +12.3% YoY · +13.0% QoQ
- Net income
- −$969,000
- −19.8% YoY · +94.9% QoQ
- Operating margin
- 4.2%
- EPS (diluted)
- $0.00
- +100.0% YoY · +100.0% QoQ
Source: XBRL data from the ARDELYX, INC. (ARDX) Q3 2025 10-Q on SEC EDGAR. USD.
ARDELYX, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: XPHOZAH excluded from Medicare Part D as of January 1, 2025, shifting coverage to ESRD PPS, materially and negatively impacting revenue
- Updated financial risk: Accumulated deficit widened to $946.5 million as of September 30, 2025, increasing pressure on achieving sustained cash flow positivity
- Regulatory risk: Inclusion of XPHOZAH in ESRD PPS alters Medicare reimbursement, adding significant commercial uncertainty and impacting pricing strategies
- Operational risk: Dependence on single-source CMOs for critical manufacturing stages increases risk of supply disruptions and potential delays in product availability
- Financial risk: Future capital needs uncertain due to commercialization costs and pipeline investments; inability to secure financing could delay clinical and business initiatives
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARDELYX, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.